Hallway Huddle: MANAGING CHRONIC KIDNEY DISEASE (CKD) IN TYPE 2 DIABETES - FOCUS ON MRAS

This program is supported by Bayer Inc. ("Bayer"). The views expressed in this program do not necessarily reflect those of Bayer. This program is limited to Canadian Healthcare Professionals. This presentation may contain information regarding indications and/or instructions that differ from the approved use of products available in Canada.

About this Program

Hear what our multidisciplinary, pan-Canadian expert panel has to say about chronic kidney disease (CKD) in patients with type 2 diabetes (T2D) in the Hallway Huddle. Each 5–10-minute video in this series features one of our experts presenting the latest on screening, guidelines, residual risk, and novel treatments for the management of CKD in T2D.

Important Disclaimer & Speaker Disclosures

.

Learning Objectives:

Question 1

When and why should patients with T2D have their UACR tested?
Navdeep Tangri, MD, PhD, FRCPC

PP-KER-CA-0077-1

Question 2

What do the guidelines say about managing CKD in T2D?
Alice Y.Y. Cheng, MD, FRCPC

PP-KER-CA-0077-1

Question 3

What are the key differences between steroidal MRAs and nonsteroidal MRAs?
Daniel Ngui, BScPT, PT, MD, CCFP, FCFP

PP-KER-CA-0077-1

Question 4

For which patients should novel nonsteroidal MRAs be considered?
Normand Proulx, MD, FRCP(C)

PP-KER-CA-0077-1

Question 5

What data supports the use of novel nonsteroidal MRAs in patients already on an SGLT2 inhibitor?
Normand Proulx, MD, FRCP(C)

PP-KER-CA-0077-1

Question 6

When and how should potassium levels be monitored and managed in patients on MRAs?
Louise Moist, MD, MSC, CCPE, FRCPC

PP-KER-CA-0077-1

Question 7

What is residual risk and why does it matter in patients with CKD and T2D?
Navdeep Tangri, MD, PhD, FRCPC

PP-KER-CA-0176-1

Question 8

Measures of albuminuria and why UACR is the gold standard for measuring cardiorenal risk?
Jordan Weinstein, MD, FRCPC

PP-KER-CA-0175-2

Question 9

UPDATE: What do the guidelines say about managing CKD in T2D?
Sara Stafford, MDCM, FRCPC

PP-KER-CA-0198-2

Question 10

What are the MOAs of the new therapies and how do they complement each other?
Normand Proulx, MD, FRCP(C)

PP-KER-CA-0177-1

Question 11

What to know about initiating and monitoring patients on finerenone?
Jordan Weinstein, MD, FRCPC

PP-KER-CA-0179-1

Question 12

What to tell patients about adding another treatment, like finerenone to their regimen?
Shelley Zieroth, MD, FCCS, FHFSA (hon), FESC, FACC, FHFA, FRCPC

PP-KER-CA-0178-1

Faculty

Alice Y.Y. Cheng

MD, FRCPC

Endocrinologist, Trillium Health Partners
& Unity Health Toronto
Associate Professor, University of Toronto
Toronto, ON

Louise Moist

MD, MSc, CCPE, FRCPC

Professor of Medicine Epidemiology and Biostatistics
Nephrologist, London Health Sciences Centre
Deputy Chair, Division of Nephrology
Schulich School of Medicine & Dentistry, Western University
London, ON

Daniel Ngui

BSc, PT, MD, CCFP, FCFP

Clinical Professor, Department of Family Medicine
University of British Columbia
Medical Director, Fraser Street Medical
Vancouver, BC

Normand Proulx

MD, FRCP(C)

Nephrologist, CISSS de l'Outaouais
Pavillon de Hull
Part-time Lecturer, McGill University
Gatineau, QC

Sara Stafford

MDCM, FRCPC

UBC Division of Endocrinology & Metabolism
Clinical Assistant Professor,
University of British Columbia

Navdeep Tangri

MD, PhD, FRCPC

Attending physician and Associate Professor
Division of Nephrology, Department of Medicine and
the Department of Community Health Sciences
University of Manitoba
Scientific Director, Chronic Disease Innovation Centre
Seven Oaks General Hospital
Winnipeg, MB

Jordan Weinstein

MD, FRCPC

Nephrologist, St. Michael's Hospital
Associate Professor of Medicine,
University of Toronto

Shelley Zieroth

MD, FCCS, FHFSA (hon), FESC, FACC, FHFA, FRCPC

Professor at the College of Medicine
Max Rady Faculty of Health Sciences
University of Manitoba

LEADING RESOURCE IN NEPHROLOGY EDUCATION

About

Partners

Follow @UKidney